Foretinib

N/A

Report date: 2023/02/03 16:50:20
NME

Base Information

Drug NameForetinib
Drug Alias Name弗瑞替尼Foretinibum佛瑞替尼EXEL-2880GSK-1363089 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 antagonistsMacrophage-stimulating protein receptor inhibitors +[8] 
TargetsVascular endothelial growth factor receptor 2Hepatocyte growth factor receptorMacrophage-stimulating protein receptor +[8] 
Therapy Area/IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG